Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Transplantation of endothelial progenitor cells attenuates pulmonary fibrosis via IFITM3-containing exosomes
Ying-Wei Lan, Jonathan Do, Wen Gao, Zicheng Deng, Xiaomei Xia, Enhong Li, Jillian Kash, Gautam Verma, Angara Sureshbabu, Kenneth S. Knox, Ross M. Bremner, Nicholas E. Banovich, Vladimir V. Kalinichenko, Tanya V. Kalin
Ying-Wei Lan, Jonathan Do, Wen Gao, Zicheng Deng, Xiaomei Xia, Enhong Li, Jillian Kash, Gautam Verma, Angara Sureshbabu, Kenneth S. Knox, Ross M. Bremner, Nicholas E. Banovich, Vladimir V. Kalinichenko, Tanya V. Kalin
View: Text | PDF
Research Article Pulmonology Vascular biology

Transplantation of endothelial progenitor cells attenuates pulmonary fibrosis via IFITM3-containing exosomes

  • Text
  • PDF
Abstract

Endothelial progenitor cells (EPCs) are critical for vascular regeneration after injury. However, their role in pulmonary fibrosis (PF) remains unclear. Here, we identified a previously unrecognized population of lung capillary EPCs coexpressing c-KIT and FOXF1 (capEPCs) in adult human and mouse lungs. capEPCs were significantly reduced in lungs from patients with PF and in bleomycin-injured mice, implicating loss of this regenerative endothelial population in disease pathogenesis. Transplantation of donor capEPCs attenuated experimental PF, improved survival, reduced collagen deposition, and restored lung function. Donor capEPCs engrafted into the lung microcirculation of bleomycin-injured mice. Single-cell RNA sequencing identified interferon-induced transmembrane protein 3 as a highly enriched transcript in capEPCs. Conditioned media from IFITM3-overexpressing EPCs or recombinant IFITM3 enhanced endothelial proliferation and angiogenesis while suppressing TGF-β1–induced fibroblast activation in vitro. IFITM3 was found in capEPC-derived exosomes. Treatment with IFITM3-containing exosomes recapitulated the therapeutic effects of capEPC transplantation by improving endothelial function, inhibiting fibroblast activation, increasing animal survival, reducing lung fibrosis, and restoring lung function. Together these findings identified capEPC deficiency as a feature of PF and demonstrated that IFITM3-containing exosomes promoted vascular repair. Restoration of capEPC regenerative function or delivery of IFITM3-enriched exosomes may represent a promising therapeutic strategy for human PF.

Authors

Ying-Wei Lan, Jonathan Do, Wen Gao, Zicheng Deng, Xiaomei Xia, Enhong Li, Jillian Kash, Gautam Verma, Angara Sureshbabu, Kenneth S. Knox, Ross M. Bremner, Nicholas E. Banovich, Vladimir V. Kalinichenko, Tanya V. Kalin

×

Figure 1

Lung capEPCs localize within CAP1 and are decreased in fibrotic lungs of PF patients.

Options: View larger image (or click on image) Download as PowerPoint
Lung capEPCs localize within CAP1 and are decreased in fibrotic lungs of...
(A) UMAP visualization of EC subclusters (n = 37,752 cells) from donor and PF lungs (GSE227136), highlighting KIT+FOXF1+ cells (capEPCs) in red. (B) Quantification of FOXF1+KIT+ capEPCs across endothelial subtypes in donor, less fibrotic PF, and more fibrotic PF lungs. Data shown as the percentage of FOXF1+KIT+ cells among total ECs, calculated separately for each sample. Each dot represents an individual donor or PF patient sample. Horizontal lines indicate mean. Statistical significance was assessed using the Kruskal-Wallis test followed by pairwise Wilcoxon’s rank-sum tests with Benjamini-Hochberg correction. (C) Reduced abundance of capEPCs in fibrotic lungs. Left: UMAP visualization showing capEPCs (red dots) in donor, less fibrotic PF, and more fibrotic PF lungs. Dashed outlines indicate capEPC-enriched region. Right: Percentage of capEPCs among total ECs: donor (n = 44), less fibrotic PF (n = 39), and more fibrotic PF (n = 49). (D) Top: Representative immunofluorescence images of donor and PF lung sections stained for CD31 (green), FOXF1 (white), KIT (red), and DAPI (blue). Bottom: CD31+, FOXF1+, and KIT+ cells are shown as percentages of total DAPI+ nuclei, and capEPCs as a percentage of total CD31+ ECs, calculated per lung sample. PF lungs showed a significant reduction in capEPCs compared with donor lungs. n = 5 lungs/group. Scale bars: 100 μm. (E) Pathway enrichment analysis of genes differentially expressed in capEPCs from donor and PF lungs. Pathways downregulated or upregulated in PF capEPCs. Data presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. One-way ANOVA, Fisher’s least significant difference (LSD).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts